498 related articles for article (PubMed ID: 18466116)
1. Huntington's disease: from pathology and genetics to potential therapies.
Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
[TBL] [Abstract][Full Text] [Related]
2. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction.
Goswami A; Dikshit P; Mishra A; Mulherkar S; Nukina N; Jana NR
Biochem Biophys Res Commun; 2006 Mar; 342(1):184-90. PubMed ID: 16472774
[TBL] [Abstract][Full Text] [Related]
5. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
[TBL] [Abstract][Full Text] [Related]
6. Polyglutamine pathogenesis.
Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
[TBL] [Abstract][Full Text] [Related]
7. Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.
Fukui H; Moraes CT
Hum Mol Genet; 2007 Apr; 16(7):783-97. PubMed ID: 17356014
[TBL] [Abstract][Full Text] [Related]
8. Genetics and neuropathology of Huntington's disease.
Reiner A; Dragatsis I; Dietrich P
Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
[TBL] [Abstract][Full Text] [Related]
9. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC
Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602
[TBL] [Abstract][Full Text] [Related]
10. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
[TBL] [Abstract][Full Text] [Related]
11. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
Wang H; Lim PJ; Karbowski M; Monteiro MJ
Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
[TBL] [Abstract][Full Text] [Related]
12. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
[TBL] [Abstract][Full Text] [Related]
13. The selective vulnerability of nerve cells in Huntington's disease.
Sieradzan KA; Mann DM
Neuropathol Appl Neurobiol; 2001 Feb; 27(1):1-21. PubMed ID: 11298997
[TBL] [Abstract][Full Text] [Related]
14. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease.
Hunter JM; Lesort M; Johnson GV
J Neurosci Res; 2007 Jun; 85(8):1774-88. PubMed ID: 17455294
[TBL] [Abstract][Full Text] [Related]
16. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice.
Wang J; Wang CE; Orr A; Tydlacka S; Li SH; Li XJ
J Cell Biol; 2008 Mar; 180(6):1177-89. PubMed ID: 18362179
[TBL] [Abstract][Full Text] [Related]
17. Molecular aspects of Huntington's disease.
Walling HW; Baldassare JJ; Westfall TC
J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
[TBL] [Abstract][Full Text] [Related]
18. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.
Borrell-Pagès M; Zala D; Humbert S; Saudou F
Cell Mol Life Sci; 2006 Nov; 63(22):2642-60. PubMed ID: 17041811
[TBL] [Abstract][Full Text] [Related]
19. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms and potential therapeutical targets in Huntington's disease.
Zuccato C; Valenza M; Cattaneo E
Physiol Rev; 2010 Jul; 90(3):905-81. PubMed ID: 20664076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
